LENS - Long-term Eltrombopag Observational Study

Completed · Has a placebo group

Conditions studied: Purpura, Thrombocytopaenic, Idiopathic

In brief

A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag. The study will follow subjects for 2.5 years following their last ocular assessment on their prior treatment study (regardless of the therapeutic indication) and will describe long-term ocular safety with respect to changes in the lenses over time from all subjects.

Key facts

Study ID

NCT00643929

Run by

GlaxoSmithKline

People needed

164

Starts

2007-02-01

Expected to finish

2013-03-01

Last updated by the study team

2017-03-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects are eligible for enrolment in the study if they have previously participated in an eltrombopag study, either phase II or III, and meet all of the following criteria:
• Subject has signed and dated a written informed consent for this study.
• Subject has previously participated in a study evaluating eltrombopag, either phase II or III, and must have received at least one dose of study medication (either active drug or placebo). This excludes subjects from phase I studies (See Section 5.1).
• The prescribed follow-up ophthalmic assessment at 6 months post end of treatment should be completed as specified in the protocol for the previous study.
• Subject is able to understand and comply with protocol requirements and instructions.

You may not qualify if…

• Subjects meeting any of the following criteria must not be enrolled in the study:
• Subject has received surgery for cataracts and is aphakic or bilaterally pseudophakic.
• In some countries (i.e. France), a subject is neither affiliated with nor a beneficiary of a social security category.

Where it is running

• GSK Investigational Site — Washington D.C., District of Columbia, United States
• GSK Investigational Site — Detroit, Michigan, United States
• GSK Investigational Site — Durham, North Carolina, United States
• GSK Investigational Site — Richmond, Virginia, United States
• GSK Investigational Site — Kogarah, New South Wales, Australia
• GSK Investigational Site — Plovdiv, Bulgaria
• GSK Investigational Site — Sofia, Bulgaria
• GSK Investigational Site — Calgary, Alberta, Canada
• GSK Investigational Site — Victoria, British Columbia, Canada
• GSK Investigational Site — Winnipeg, Manitoba, Canada
• GSK Investigational Site — Halifax, Nova Scotia, Canada
• GSK Investigational Site — Montreal, Quebec, Canada
• GSK Investigational Site — Brno, Czechia
• GSK Investigational Site — Prague, Czechia
• GSK Investigational Site — Prague, Czechia
• GSK Investigational Site — Caen, France
• GSK Investigational Site — Clichy, France
• GSK Investigational Site — Marseille, France
• GSK Investigational Site — Paris, France
• GSK Investigational Site — Pessac, France
• GSK Investigational Site — Rouen, France
• GSK Investigational Site — Vandœuvre-lès-Nancy, France
• GSK Investigational Site — Berlin, State of Berlin, Germany
• GSK Investigational Site — Shatin, New Territories, Hong Kong
• GSK Investigational Site — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.